From Bacterial Toxin to Therapeutic Agent: The Unexpected Fate of Mycolactone - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Toxins Année : 2023

From Bacterial Toxin to Therapeutic Agent: The Unexpected Fate of Mycolactone

Résumé

“Recognizing a surprising fact is the first step towards discovery.” This famous quote from Louis Pasteur is particularly appropriate to describe what led us to study mycolactone, a lipid toxin produced by the human pathogen Mycobacterium ulcerans. M. ulcerans is the causative agent of Buruli ulcer, a neglected tropical disease manifesting as chronic, necrotic skin lesions with a “surprising” lack of inflammation and pain. Decades after its first description, mycolactone has become much more than a mycobacterial toxin. This uniquely potent inhibitor of the mammalian translocon (Sec61) helped reveal the central importance of Sec61 activity for immune cell functions, the spread of viral particles and, unexpectedly, the viability of certain cancer cells. We report in this review the main discoveries that marked our research into mycolactone, and the medical perspectives they opened up. The story of mycolactone is not over and the applications of Sec61 inhibition may go well beyond immunomodulation, viral infections, and oncology.
Fichier principal
Vignette du fichier
toxins-15-00369-v2.pdf (623.14 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

pasteur-04376976 , version 1 (07-01-2024)

Licence

Paternité

Identifiants

Citer

Daniela Ricci, Caroline Demangel. From Bacterial Toxin to Therapeutic Agent: The Unexpected Fate of Mycolactone. Toxins, 2023, 15 (6), pp.369. ⟨10.3390/toxins15060369⟩. ⟨pasteur-04376976⟩

Collections

PASTEUR FRM
21 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More